- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
Status change linked to topic prioritisation decision being set to Selected
- Process:
- STA Standard
- ID number:
- 6496
Provisional Schedule
- In progress. Status change linked to topic prioritisation decision being set to Selected:
- 17 February 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- School of Health and Related Research (ScHARR), University of Sheffield
Stakeholders
- Companies sponsors
- Deciphera Pharmaceuticals (ripretinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- GIST Cancer UK
- PAWS-GIST Clinic
- Sarcoma UK
- Professional groups
- Association of Cancer Physicians
- British Society of Gastroenterology
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 February 2026 | This appraisal will be paused at the request of the company until NICE has the power to apply the new cost-effectiveness threshold. NICE anticipates that its cost-effectiveness threshold will increase in April 2026 and we will provide a further update to stakeholders at that time. More information about changes to NICE’s cost-effectiveness thresholds can be found here: https://www.nice.org.uk/news/articles/changes-to-nice-s-cost-effectiveness-thresholds-confirmed |
| 07 January 2026 | Committee meeting: 2 |
| 12 November 2025 - 03 December 2025 | Draft guidance |
| 15 October 2025 | Committee meeting: 1 |
| 15 October 2025 | Declaration of interests |
| 17 March 2025 | Invitation to participate |
| 27 January 2025 - 25 February 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 28 January 2025 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual